Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.41 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483001 | 0.92 | KMT2A (0.46) | KMT2AMEN1MAPTSLC16A3SLC16A1 | |
| SCHEMBL7166657 | 0.86 | TRPM8 (0.42) | KMT2AMEN1MAPTTRPM8ALOX5 | |
| SCHEMBL4487336 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1MAPTSLC16A3SLC16A1 | |
| SCHEMBL7204107 | 0.79 | MAPT (0.42) | KMT2AMEN1MAPTALOX5EGFR | |
| SCHEMBL4481022 | 0.77 | PKM (0.54) | KMT2AMEN1MAPTEGFRALDH1A1 | |
| SCHEMBL4481016 | 0.77 | PKM (0.54) | KMT2AMEN1MAPTEGFRALDH1A1 | |
| SCHEMBL1551528 | 0.76 | MAOB (0.60) | KMT2AMEN1MAPTALOX5EGFR | |
| SCHEMBL1551530 | 0.76 | MAOB (0.60) | KMT2AMEN1MAPTALOX5EGFR | |
| SCHEMBL4489692 | 0.75 | MCL1 (0.70) | KMT2AMEN1MAPTALOX5EGFR | |
| SCHEMBL4489689 | 0.75 | MCL1 (0.70) | KMT2AMEN1MAPTALOX5EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598419-B2 | Compounds for modulating cell proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2009-10-06 | — | — | US | disclosed |
| US-20070243612-A1 | Novel Compounds for Modulating Cell Proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2007-10-18 | — | — | US | disclosed |
| EP-1727822-A4 | NOVEL COMPOUNDS FOR MODULATING CELL PROLIFERATION | HSC RES DEV LP (CA) | 2007-05-09 | — | — | EP | disclosed |
| EP-1727822-A1 | NOVEL COMPOUNDS FOR MODULATING CELL PROLIFERATION | HSC Research and Development Limited Partnership (CA) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005092904-A1 | NOVEL COMPOUNDS FOR MODULATING CELL PROLIFERATION | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2005-10-06 | — | — | WO | disclosed |
| US-6800659-B2 | NOVEL STYRYLACRYLONITRILE COMPOUNDS WHICH ARE USEFUL IN TREATING A VARIETY OF CELL PROLIFERATIVE DISORDERS SUCH AS CANCER ARE DISCLOSED. A METHOD OF MODULATING CELL PROLIFERATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2004-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243612-A1 | Novel Compounds for Modulating Cell Proliferation | MKI67, CCNA1, PCNA | KMT2A 3146/4885MEN1 2749/4885MAPT 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.